Zydus Lifesciences Receives USFDA EIR for Injectable Facility in Ahmedabad

Zydus Lifesciences has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility at Zydus Biotech Park in Ahmedabad. The company disclosed the development in a regulatory filing dated 1 August 2026. 

The regulator has classified the facility as Voluntary Action Indicated (VAI) following a Good Manufacturing Practices (GMP) surveillance inspection.  

Inspection Conducted Between April and May 

The USFDA inspected the injectable facility from 27 April to 5 May 2026 as part of its routine GMP surveillance programme. Following its review of the inspection findings, the regulator issued the EIR, formally concluding the inspection process for the site.  

The filing does not provide details of the observations made during the inspection.  

VAI Classification 

A Voluntary Action Indicated classification means the USFDA identified observations during the inspection that may require corrective action by the manufacturer.  

At the same time, the classification indicates that the agency has not initiated regulatory or enforcement action against the facility based on the inspection. 

The EIR is issued after the USFDA completes its assessment of the inspection and any responses submitted by the company. The receipt of the report marks the completion of that review process for the Ahmedabad plant.  

Disclosure to Stock Exchanges 

Zydus Lifesciences informed both the BSE and the National Stock Exchange about the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.  

The company stated that the disclosure relates to its injectable facility located at Zydus Biotech Park, Ahmedabad.  

Read More: GAIL Share Price Up Over 4%; Approves Scheme of Merger of Konkan LNG with Company! 

Zydus Lifesciences Share Price Performance  

As of July 31, 2026, 3:30 pm, Zydus Lifesciences Ltd share price closed at ₹1,125.00, up 0.89% from the previous closing price. 

Conclusion 

The receipt of the EIR concludes the USFDA inspection process for Zydus' injectable manufacturing facility at Zydus Biotech Park, Ahmedabad. The company disclosed the development through a regulatory filing under SEBI's listing regulations. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.